China's Exports to US Fall Most Since 2020 Despite Trade Truce
Chinese exports rose less than expected last month as the worst drop in shipments to the US in more than five years counteracted strong demand from other markets.
Exports rose 4.8% from a year ago to $316 billion in May, slower than the 6% median growth forecast in a survey of economists. Imports fell 3.4% for a third straight month of declines, leaving a trade surplus of $103 billion, according to official data Monday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
33 minutes ago
- Wall Street Journal
Global Markets Mixed; U.S.-China Trade Talks in Focus
U.S. stock futures pointed to a slightly lower open Monday after gains last week buoyed by optimism around U.S.-China trade talks, and after the U.S. jobs market held up better than expected. The main focus this week is on those trade talks in London, while U.S. inflation data for May are due on Wednesday.
CNN
33 minutes ago
- CNN
US and China kick off fresh round of trade talks in London over intractable issues
A new round of trade negotiations between the United States and China is set to begin Monday in London as both sides try to preserve a fragile truce brokered last month. The fresh talks were announced last week after a long-anticipated phone call between US President Donald Trump and Chinese leader Xi Jinping, which appeared to ease tensions that erupted over the past month following a surprise agreement in Geneva. In May, the two sides agreed to drastically roll back tariffs on each other's goods for an initial 90-day period. The mood was upbeat. However, sentiment soured quickly over two major sticking points: China's control over so-called rare earths minerals and its access to semiconductor technology originating from the US. Beijing's exports of rare earths and their related magnets are expected to take center stage at the London meeting. But experts say Beijing is unlikely to give up its strategic grip over the essential minerals, which are needed in a wide range of electronics, vehicles and defense systems. 'China's control over rare earth supply has become a calibrated yet assertive tool for strategic influence,' Robin Xing, Morgan Stanley's chief China economist and other analysts wrote in a Monday research note. 'Its near-monopoly of the supply chain means rare earths will remain a significant bargaining chip in trade negotiations.' Since the talks in Geneva, Trump has accused Beijing of effectively blocking the export of rare earths, announcing additional chip curbs and threatening to revoke the US visas of Chinese students. The moves have provoked backlash from China, which views Washington's decisions as reneging on its trade promises. All eyes will be on whether both sides can come to a consensus in London on issues of fundamental importance. US Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and Trade Representative Jamieson Greer will meet a Chinese delegation led by Vice Premier He Lifeng. On Saturday, Beijing appeared to send conciliatory signals. A spokesperson for China's Commerce Ministry, which oversees the export controls, said it had 'approved a certain number of compliant applications.' 'China is willing to further enhance communication and dialogue with relevant countries regarding export controls to facilitate compliant trade,' the spokesperson said. Kevin Hassett, head of the National Economic Council at the White House, told CBS's Face the Nation on Sunday that the US side would be looking to restore the flow of rare earth minerals. 'Those exports of critical minerals have been getting released at a rate that is higher than it was, but not as high as we believe we agreed to in Geneva,' he said, adding that he is 'very comfortable' with a trade deal being made after the talks. In April, as tit-for-tat trade tension between the two countries escalated, China imposed a new licensing regime on seven rare earth minerals and several magnets, requiring exporters to seek approvals for each shipment and submit documentation to verify the intended end use of these materials. Following the trade truce negotiated in Geneva, the Trump administration expected China to lift restrictions on those minerals. But Beijing's apparent slow-walking of approvals triggered deep frustration within the White House, CNN reported last month. Rare earths are a group of 17 elements that are more abundant than gold and can be found in many countries, including the United States. But they're difficult, costly and environmentally polluting to extract and process. China controls 90% of global rare earth processing. Experts say it's possible that Beijing may seek to use its leverage over rare earths to get Washington to ease its own export controls aimed at blocking China's access to advanced US semiconductors and related technologies. The American Chamber of Commerce in China said on Friday that some Chinese suppliers of American companies have received six-month export licenses. Reuters also reported that suppliers of major American carmakers – including General Motors, Ford and Jeep-maker Stellantis – were granted temporary export licenses for a period of up to six months. While China may step up the pace of license approvals to cool the diplomatic temperature, global access to Chinese rare earth minerals will likely remain more restricted than it was before April, according to a Friday research note by Leah Fahy, a China economist and other experts at Capital Economics, a London-based consultancy. 'Beijing had become more assertive in its use of export controls as tools to protect and cement its global position in strategic sectors, even before Trump hiked China tariffs this year,' the note said. As China tackles a tariff war with the US head on, it's clear that it is continuing to cause economic pain at home. Trade data released Monday painted a gloomy picture for the country's export-reliant economy. Its overall overseas shipments rose by just 4.8% in May compared to the same month a year earlier, according to data released by China's General Administration of Customs. It was a sharp slowdown from the 8.1% recorded in April, and lower than the estimate of 5.0% export growth from a Reuters poll of economists. Its exports to the US suffered a steep decline of 34.5%. The sharp monthly fall widened from a 21% drop in April and came despite the trade truce announced on May 12 that brought American tariffs on Chinese goods down from 145% to 30%. Still, Lv Daliang, a spokesperson for the customs department, talked up China's economic strength, telling the state-run media Xinhua that China's goods trade has demonstrated 'resilience in the face of external challenges.' Meanwhile, deflationary pressures continue to stalk the world's second-largest economy persist, according to data released separately on Monday by the National Bureau of Statistics (NBS). In May, China's Consumer Price Index (CPI), a benchmark for measuring inflation, dropped 0.1% compared to the same month last year. Factory-gate deflation, measured by the Producer Price Index (PPI), worsened with a 3.3% decrease in May from a year earlier. Last month's drop marks the sharpest year-on-year contraction in 22 months, according to NBS data. Dong Lijuan, chief statistician at the NBS, attributed the decline in producer prices, which measures the average change in prices received by producers of goods and services, to a drop in global oil and gas prices, as well as the decrease in prices for coal and other raw materials due to low cyclical demand. The high base of last year was cited as another reason for the decline, Dong said in a statement. CNN's Hassan Tayir, Simone McCarthy, Fred He contributed reporting.
Yahoo
40 minutes ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
